poisar

Stocks · News reference

8-K filing — Dare Bioscience, Inc. (DARE)

SEC EDGARAug 17, 2026, 12:35 PMSEC EDGAR

Filed: 2026-08-17 AccNo: 0001493152-26-038649 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Aug 17, 2026, 12:35 PM
Checked
Aug 17, 2026, 12:35 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaAug 26, 2026, 12:47 PMBenzinga Newsdesk

    Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure

    The peer-reviewed article, titled, "A phase 1, open-label, within-participant dose-escalation study to evaluate the safety and pharmacokinetics of topical sildenafil cream in healthy postmenopausal women,"

    Read original at benzinga